Recent Quotes (30 days)

You have no recent quotes
chg | %

Aptose Biosciences Inc  

(Public, TSE:APS)   Watch this stock  
Find more results for TSE:LOR
-0.08 (-3.20%)
Oct 21 - Close
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 2.42 - 2.59
52 week 2.42 - 8.33
Open 2.50
Vol / Avg. 51,345.00/28,904.00
Mkt cap 30.33M
P/E     -
Div/yield     -
EPS -1.52
Shares 13.04M
Beta 1.15
Inst. own     -
Nov 8, 2016
Q3 2016 Aptose Biosciences Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Oct 13, 2016
Aptose Biosciences Inc Conference Call to Discuss on FDA Clinical Hold of APTO-253 - Webcast
Aug 11, 2016
Aptose Biosciences Inc at Canaccord Genuity Growth Conference - Webcast
Aug 9, 2016
Q2 2016 Aptose Biosciences Inc Earnings Call
Aug 9, 2016
Q2 2016 Aptose Biosciences Inc Earnings Release

Key stats and ratios

Q2 (Jun '16) 2015
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -151.35% -55.35%
Return on average equity -172.57% -60.73%
Employees 22 -
CDP Score - -


5955 Airport Rd Suite 228
+1-647-4799828 (Phone)
+1-416-7982200 (Fax)

Website links


Aptose Biosciences Inc. (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities. The Company develops therapeutics focused on epigenetic processes and signal transduction abnormalities at the edge of cancer research, coupled with companion diagnostics to identify the optimal patient population for its products. The Company's APTO-253 is a small molecule that can induce expression of the genes that codes for the Kruppel-like factor 4 (KLF4) master transcription factor and the p21 cell cycle inhibitor protein.

Officers and directors

William Glenn Rice Chairman of the Board, President, Chief Executive Officer
Gregory Kwok Lee Chow Chief Financial Officer, Senior Vice President
Avanish Vellanki Senior Vice President, Chief Business Officer
Denis R. Burger Ph.D. Independent Director
Age: 70
Erich M. Platzer M.D., Ph.D. Independent Director
Bradley Thompson Independent Director
Mark D. Vincent M.D. Independent Director
Warren Whitehead Independent Director